

Venue	Conference building				Exhibition building	
	Main Hall	Tachibana Conference Hall	Hagi Conference Hall	Shirakashi Conference Room	Meeting Room 1&2	Exhibition Hall
2/18AM 10:00-12:30	<b>Opening 10:00~10:30</b>					Exhibition Poster 9:00~17:00
	<b>K-01 10:30~11:30 Keynote1</b> AI-driven pharmaceutical innovation in Japan					
	<b>K-02 11:30~12:30 Keynote2</b> Medical response to the Great East Japan Earthquake in the Ishinomaki Medical Zone					
<b>Lunch</b>					Poster Short Oral 12:45~13:55	
2/18PM 14:15-18:05	<b>C-01 14:15~15:30</b> JSQA-JMACCT Considerations for Using IT Systems in Clinical Trials	<b>X-01 14:15~15:55</b> Up-to-date initiatives for promoting clinical trials and Quality Assurance in Asian countries.	<b>L-02 14:15~15:35</b> Points to be noted when outsourcing non-clinical studies (GLP studies, non-GLP studies) to domestic facilities.		<b>Oral Presentations</b> <b>O-01</b> 14:15~14:45 <b>O-02</b> 14:45~15:15 <b>O-03</b> 15:15~15:45	
	Break	Break	Break		Break	
	<b>X-02 16:00~18:05</b> Compliance and quality assurance in the integrity of the utilized electrical data in Pharmaceutical industry	<b>L-01 16:25~17:55</b> The history behind the FDA GLP	<b>L-03 16:05~18:00</b> Points to be noted when outsourcing non-clinical studies (non-GLP, PK and Pharmacology studies) to overseas facilities.		<b>Oral Presentations</b> <b>O-04</b> 16:15~16:45 <b>O-05</b> 16:45~17:15 <b>O-06</b> 17:15~17:45	
2/19AM 9:00-12:00	<b>L-04 9:00~10:15</b> Promoting quality in research in the academic environment	<b>L-05 9:00~10:15 / 10:45~12:00</b> (10:15~10:45 Break) Future of Electronic Archiving	<b>X-03 9:10~10:15 / 10:45~11:50</b> (10:15~10:45 Break 30m) Current status and issues of clinical analysis-related regulations in each country	<b>X-04 9:00~10:15</b> The investigational medicinal products GMP in Japan (J-GMP for IMP)	<b>Oral Presentations</b> <b>O-07</b> 9:15~9:45 <b>O-08</b> 9:45~10:15	Exhibition Poster 9:00~17:00
	Break			Break	Break	
	<b>C-02-1 10:45~12:00</b> Different or Same? GCP Requirements among Regulatory Authorities -Subject Protection and Informed Consent Process -			<b>X-05 10:45~12:00</b> Embark on the New Tide! PV QMS culture in Japan and Asia	<b>Oral Presentations</b> <b>O-09</b> 10:45~11:15 <b>O-10</b> 11:15~11:45	
<b>Lunch</b>						Poster discussion 12:10~13:50
2/19PM 14:00-18:00	<b>C-02-2 14:00~16:00</b> Different or Same? GCP Requirements among Regulatory Authorities -GCP Inspections -	<b>L-06 14:00~15:55 / 16:25~17:25</b> (15:55~16:25 Break) What has changed by issuing OECD Advisory Document No.19?	<b>X-06 14:30~16:00/ 16:30~17:50</b> (16:00~16:30 Break) Current status of regenerative therapeutic products and Quality Assurance	<b>L-07 14:00~16:00</b> Role of QAU at the testing facility in the event of a disaster		
	Break			Break	Break	
	<b>C-02-3 16:30~18:00</b> Different or Same? GCP Requirements among Regulatory Authorities - Data Integrity in Clinical Trials -			<b>L-08 16:30~18:00</b> “SAMURAI” and “Quality Assurance”		
2/20AM 9:00-12:40	<b>X-07 9:00~9:45</b> Basics in keeping Quality					Exhibition Poster 9:00~10:30
	Break					
	<b>X-08 10:10~12:10</b> GxP Regulatory Session					
	<b>Closing 12:10~12:40</b>					